Market Overview
Parathyroid disorders are conditions that affect the parathyroid glands, which are four small glands located in the neck that regulate the body's calcium levels. These disorders include hyperparathyroidism, hypoparathyroidism, and parathyroid cancer.
The global parathyroid disorders market is expected to grow significantly in the coming years, driven by several factors such as an increasing prevalence of parathyroid disorders, rising healthcare expenditure, and technological advancements in diagnostic tools and treatment options.
Hyperparathyroidism is the most common parathyroid disorder, accounting for the majority of cases. It is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH), leading to elevated calcium levels in the blood. The rising prevalence of hyperparathyroidism is expected to drive the growth of the market. According to a study published in the Journal of Clinical Endocrinology and Metabolism, the prevalence of primary hyperparathyroidism is estimated to be 0.16% in the United States.
Hypoparathyroidism is another parathyroid disorder, which occurs when the parathyroid glands do not produce enough PTH. The rising prevalence of hypoparathyroidism, coupled with the increasing awareness about the condition, is expected to drive the growth of the market.
Parathyroid cancer is a rare type of cancer that originates in the parathyroid glands. The increasing prevalence of parathyroid cancer is expected to drive the growth of the market.
Geographically, North America is expected to dominate the parathyroid disorders market, followed by Europe. This is due to the high prevalence of parathyroid disorders in these regions, coupled with the presence of well-established healthcare infrastructure and increasing healthcare expenditure. The Asia-Pacific region is expected to grow at a significant rate during the forecast period, driven by the increasing prevalence of parathyroid disorders and rising healthcare expenditure in the region.
Segment Overview
The parathyroid disorders market can be segmented based on the type of disorder and the mode of treatment.
Based on the type of disorder, the market can be segmented into:
1. Hyperparathyroidism: This is a condition where the parathyroid glands produce too much parathyroid hormone (PTH), leading to high levels of calcium in the blood. Hyperparathyroidism can be primary, secondary or tertiary.
2. Hypoparathyroidism: This is a condition where the parathyroid glands produce too little PTH, leading to low levels of calcium in the blood.
Based on the mode of treatment, the market can be segmented into:
1. Drugs: Calcium and vitamin D supplements are often used to treat parathyroid disorders. Other drugs that can be used to treat hyperparathyroidism include bisphosphonates, calcimimetics, and denosumab.
2. Surgery: Surgery is the most common treatment for parathyroid disorders. In cases of hyperparathyroidism, surgery involves removing the affected parathyroid gland(s). In cases of hypoparathyroidism, surgery may involve transplanting parathyroid tissue or implanting a device that delivers PTH.
3. Other treatments: Other treatments for parathyroid disorders include radiation therapy, which is sometimes used to shrink tumors that are causing hyperparathyroidism, and dialysis, which is sometimes used to manage high levels of calcium in the blood caused by kidney failure.
Overall, the parathyroid disorders market is expected to grow in the coming years, driven by an increasing incidence of these disorders and the development of new and more effective treatments.
Geographical Overview
The market for parathyroid disorders can vary geographically, depending on factors such as population demographics, access to healthcare, and prevalence of the disorders. However, parathyroid disorders are relatively rare conditions, affecting only a small percentage of the population.
In general, developed countries with better access to healthcare tend to have higher rates of diagnosis and treatment for parathyroid disorders. North America and Europe are major markets for parathyroid disorders, with the United States being the largest market due to its large population and well-developed healthcare system. In Europe, Germany, the UK, and France are the largest markets for parathyroid disorders.
Asia-Pacific is a growing market for parathyroid disorders, with increasing awareness and diagnosis of the conditions in countries such as China, Japan, and South Korea. Other regions such as Latin America and the Middle East & Africa also have potential for growth in the parathyroid disorders market, but this is largely dependent on healthcare infrastructure and access to treatment.
COVID Impact
The COVID-19 pandemic has had a significant impact on the healthcare industry and has disrupted the global economy. The parathyroid disorders market has also been affected by the pandemic.
One of the primary factors affecting the parathyroid disorders market is the disruption in the supply chain of pharmaceuticals and medical devices due to the pandemic. The lockdowns and travel restrictions imposed by various countries have led to delays in the production, shipment, and distribution of drugs and medical equipment, including those used for the treatment of parathyroid disorders.
Furthermore, the pandemic has resulted in a reduction in patient visits to hospitals and clinics, leading to a decrease in the diagnosis and treatment of parathyroid disorders. Patients with parathyroid disorders may also be hesitant to visit healthcare facilities due to the risk of exposure to the virus. This has resulted in a significant decline in the demand for parathyroid disorder treatments.
The COVID-19 pandemic has also led to a diversion of healthcare resources and funding towards COVID-19 treatment and research, leading to a decrease in investment and research in the parathyroid disorders market.
Despite the challenges posed by the pandemic, the parathyroid disorders market is expected to recover gradually as the vaccination rates increase, and the situation improves. The growing prevalence of parathyroid disorders, coupled with the rising geriatric population, is expected to drive the demand for parathyroid disorder treatments in the long run.
Competitive Analysis
The parathyroid disorders market is expected to grow significantly in the coming years due to the increasing prevalence of these disorders and the growing aging population. The market is highly competitive, with several established players and new entrants vying for market share. Here is a competitive analysis of the key players in the parathyroid disorders market:
1. Amgen Inc.: Amgen is a leading player in the parathyroid disorders market, with its flagship product Sensipar/Mimpara. The drug is approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease and hypercalcemia in patients with parathyroid carcinoma. The company has a strong distribution network and a wide range of products in its pipeline.
2. F. Hoffmann-La Roche Ltd: Roche is another major player in the parathyroid disorders market, with its drug Parsabiv. The drug is used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. The company has a strong R&D pipeline and is constantly investing in research to develop new treatments for parathyroid disorders.
3. AbbVie Inc.: AbbVie is a leading pharmaceutical company with a strong presence in the parathyroid disorders market. Its drug, Orilissa, is used for the treatment of endometriosis, a condition that can lead to secondary hyperparathyroidism. The company has a wide range of products in its pipeline and is constantly exploring new treatment options for parathyroid disorders.
4. Teva Pharmaceutical Industries Ltd.: Teva is a leading player in the parathyroid disorders market, with its drug, Cinacalcet Hydrochloride. The drug is used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease and hypercalcemia in patients with parathyroid carcinoma. The company has a strong distribution network and a wide range of products in its pipeline.
5. Pfizer Inc.: Pfizer is a leading pharmaceutical company with a strong presence in the parathyroid disorders market. Its drug, Genotropin, is used for the treatment of growth hormone deficiency, which can lead to secondary hyperparathyroidism. The company has a strong R&D pipeline and is constantly exploring new treatment options for parathyroid disorders.
Other notable players in the parathyroid disorders market include Eli Lilly and Company, Novartis AG, Merck & Co., Inc., and Sanofi S.A. These companies are also investing heavily in R&D to develop new treatments for parathyroid disorders and expand their market share.